200 completed, 63 unknown, 59 recruiting, 36 terminated. 422 Phase 3, 53 Phase 2.
By phase and status
Phase Trials Status Phase 3 422 Completed 200 , Unknown 63 , Recruiting 59 , Terminated 36 , Active not recruiting 35 , Not yet recruiting 16 , Withdrawn 11 , Suspended 2 Phase 2 53 Completed 24 , Recruiting 10 , Unknown 8 , Terminated 6 , Active not recruiting 3 , Not yet recruiting 1 , Withdrawn 1
Follow Adnexal Diseases: new trials by email Literature Review of Adnexal Diseases trials Research Report on Adnexal Diseases
Trials (filtered) newest first · largest first
All 422 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1 INCB123667, Bevacizumab, Placebo - Ovarian Cancer Phase 3 Not yet recruiting 590 2026-12-01 2026-10-02 Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer Rina-S, Bevacizumab - Ovarian Cancer Phase 3 Not yet recruiting 602 2026-11-01 2026-10-05 A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer Manganese Chloride, Nab-paclitaxel, Platinum chemotherapy - Ovarian Cancer Phase 3 Recruiting 120 2026-10-12 2026-09-16 Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03] Mocertatug rezetecan, Bevacizumab - Ovarian Neoplasms Phase 3 Not yet recruiting 720 2026-10-09 2026-10-02 A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) R-DXd, Bevacizumab, Carboplatin - Ovarian Cancer, Peritoneal Cancer Phase 3 Recruiting 646 2026-10-07 2026-10-30 A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) R-DXd, Bevacizumab - Fallopian Tube Cancer, Primary Peritoneal Cancer Phase 3 Not yet recruiting 600 2026-10-01 2026-09-01 Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) - Colorectal Cancer, Gastric Cancers Phase 2 / Phase 3 Recruiting 175 2026-10-01 2026-06-17 Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers BG-C9074, Bevacizumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer Phase 3 Not yet recruiting 600 2026-10-01 2026-09-10 Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Torvutatug samrotecan, Bevacizumab - Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer Phase 3 Recruiting 600 2026-09-24 2026-10-16 A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) R-DXd, Bevacizumab - Ovarian Cancer, Ovarian Neoplasms Phase 3 Recruiting 802 2026-09-18 2026-10-29 Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer Torvutatug samrotecan, Bevacizumab - Epithelial Ovarian Cancer Phase 3 Recruiting 950 2026-09-16 2026-10-01 A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02) Mocertatug rezetecan (Mo-Rez), Carboplatin, Paclitaxel - Ovarian Neoplasms Phase 3 Recruiting 690 2026-09-08 2026-10-01 Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer trastuzumab, bevacizumab - Ovarian Cancer Phase 3 Not yet recruiting 420 2026-09-01 2026-08-21 Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer Rina-S, Bevacizumab, Carboplatin - Platinum-Sensitive Ovarian Cancer, Ovarian Cancer Phase 3 Recruiting 688 2026-08-28 2026-10-07 A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer BL-M07D1, Liposomal Doxorubicin, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer Phase 3 Not yet recruiting 404 2026-07-01 2026-06-29 An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China Rina-S, Paclitaxel, Topotecan - Platinum-resistant Ovarian Cancer Phase 3 Recruiting 82 2026-06-26 2026-10-06 A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) Mocertatug rezetecan, Paclitaxel, Pegylated liposomal doxorubicin (PLD) - Ovarian Neoplasms Phase 3 Recruiting 450 2026-06-18 2026-10-15 Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A GnRH antagonist, MPA - Preimplantation Genetic Testing, Progestin-primed Ovarian Stimulation Phase 3 Not yet recruiting 204 2026-06-01 2026-02-02 Tiaoshen Anti-cancer Protocol and CBT for Insomnia and Survival in Ovarian Cancer Tiaoshen Anti-cancer Granules, Placebo Granules, Cognitive Behavioral Therapy for Insomnia - Ovarian Neoplasms Malignant, Sleep Initiation and Maintenance Disorders Phase 2 / Phase 3 Not yet recruiting 360 2026-05-01 2026-04-24 A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression Investigator's choice of Chemotherapy, Azenosertib - Ovarian Cancer Phase 3 Recruiting 420 2026-04-17 2026-08-12
Showing 20 of 422. Sign in to see all of them.
Narrower conditions Ovarian Neoplasms (261) · Fallopian Tube Neoplasms (110) · Carcinoma, Ovarian Epithelial (96) · Polycystic Ovary Syndrome (80) · Breast Neoplasms (26) · Neoplasms (26) · Peritoneal Neoplasms (16) · Endometrial Neoplasms (15) · Infertility (15) · Recurrence (14) · Uterine Cervical Neoplasms (14) · Brenner Tumor (13) · Testicular Neoplasms (13) · Multiple Myeloma (12) · Burkitt Lymphoma (11)
Broader conditions Female Urogenital Diseases (422) · Female Urogenital Diseases and Pregnancy Complications (422) · Genital Diseases (422) · Urogenital Diseases (422) · Genital Diseases, Female (421) · Gonadal Disorders (414) · Ovarian Diseases (413) · Endocrine System Diseases (412) · Neoplasms (369) · Urogenital Neoplasms (309) · Neoplasms by Site (307) · Genital Neoplasms, Female (306) · Endocrine Gland Neoplasms (301) · Neoplasms by Histologic Type (126)
Interventions Paclitaxel (98) · Carboplatin (75) · Bevacizumab (49) · liposomal doxorubicin (39) · Topotecan (35) · Gemcitabine (29) · Metformin (29) · Cisplatin (21) · Letrozole (19) · olaparib (19) · Drug Therapy (16) · Taxes (15) · Doxorubicin (14) · Clomiphene (10) · Hyperthermic Intraperitoneal Chemotherapy (10)
Sponsors AstraZeneca (13) · National Cancer Institute (NCI) (10) · Gynecologic Oncology Group (9) · AGO Study Group (8) · Medical Research Council (7) · Merck Sharp & Dohme LLC (7) · European Organisation for Research and Treatment of Cancer - EORTC (6) · Pfizer (6) · Beni-Suef University (5) · Genmab (5) · Hoffmann-La Roche (5) · National Cancer Institute, Naples (5) · Amgen (4) · Jiangsu HengRui Medicine Co., Ltd. (4) · Merck KGaA, Darmstadt, Germany (4)
Countries United States (156) · Italy (87) · United Kingdom (80) · China (78) · Spain (78) · France (74) · Canada (70) · Germany (69) · Belgium (68) · South Korea (63) · Japan (50) · Poland (50) · Australia (49) · Israel (45) · Denmark (40)
Top investigators Francesco Perrone, M.D., Ph.D. (3) · Ignace B. Vergote, MD, PhD (3) · Jacobus Pfisterer, MD (3) · Jalid Sehouli (3) · Sandro Pignata, M.D., Ph.D. (3) · Cary Presant, MD (2)
Results publications PMID 37185961 , PMID 37407274 , PMID 35170751 , PMID 39695768 , PMID 21941283 , PMID 30633128 , PMID 16882940 , PMID 16966687 , PMID 20818904 , PMID 21645894 , PMID 25324541 , PMID 26354094 , PMID 30186323 , PMID 33960681 , PMID 39019698 , PMID 10481771 , PMID 10655437 , PMID 11165136 , PMID 11304695 , PMID 11479630 , PMID 11527911 , PMID 12826431 , PMID 12829663 , PMID 12860964 , PMID 14656276 , PMID 14688154 , PMID 15459300 , PMID 15547181 , PMID 15839957 , PMID 16110020 , PMID 16148284 , PMID 16239238 , PMID 16314640 , PMID 16368440 , PMID 16394300 , PMID 16515585 , PMID 16543255 , PMID 16791447 , PMID 16849762 , PMID 16912194 , PMID 17264340 , PMID 17287476 , PMID 17489756 , PMID 17698804 , PMID 17704410 , PMID 17906207 , PMID 17925548 , PMID 17949799 , PMID 17980364 , PMID 18000088
NIH funding U10CA180868 (12) , 2025 (10) , U10CA027469 (9) , 2023 (7) , 2018 (6) , 2008 (5) , 2017 (4) , 2019 (4) , 2009 (3) , 2015 (3) , 2004 (2) , 2016 (2) , U10CA032102 (2) , U10CA101165 (2) , 2005 (1)